Skip to main content

Rheumatoid Arthritis

      RT @RichardPAConway: Great talks on comorbidities in RA at #EULAR2021 today. What do we struggle most with in RA managem

      Richard Conway RichardPAConway

      4 years 3 months ago
      Great talks on comorbidities in RA at #EULAR2021 today. What do we struggle most with in RA management? @RheumNow
      Cardiovascular (CV) disease remains the leading cause of mortality in rheumatoid arthritis (RA). A number of studies progressed our knowledge in the session Rheumatoid arthritis - comorbidity and clinical aspects – I on Thursday at EULAR 2021.
      RT @Janetbirdope: RA ILD will kill pts esp UIP pattern and extent & presence of honeycombing on HRCT. Think about it

      Janet Pope Janetbirdope

      4 years 3 months ago
      RA ILD will kill pts esp UIP pattern and extent & presence of honeycombing on HRCT. Think about it esp if older pt #EULAR2021 #BoehringerIngelheim symposium @RheumNow @eular_org https://t.co/be2Z7KMqpg
      RT @Stiddyo: #POS0093 Collaborative registry studies are to be encouraged! BUT
      @k_lauper outlines the heterogenity betwe

      Paul Studenic Stiddyo

      4 years 3 months ago
      #POS0093 Collaborative registry studies are to be encouraged! BUT @k_lauper outlines the heterogenity between registries concerning #AE reporting - Jak-pot study - 18 registries with #RA patients on #tofacitinib - Rates of discontinuation vary across registry #EULAR2021 @RheumNow https://t.co/oczJAG8hzv
      RT @AurelieRheumo: An original way of differentiating RA from PsA!
      The shape of the second MCP in HR-pQCT is enough to

      Aurelie Najm AurelieRheumo

      4 years 3 months ago
      An original way of differentiating RA from PsA! The shape of the second MCP in HR-pQCT is enough to train a neural network with high accuracy for recognition of -HC 94% -RA 84% -PsA 89% and an AUC of 91%. #EULAR2021 @RheumNow #OP0145 https://t.co/BrwFQpX310
      After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.
      RT @Janetbirdope: What is largest ⬆️ infection risk in RA? steroids, past infection, age, DM? Host factors & Pr

      Janet Pope Janetbirdope

      4 years 3 months ago
      What is largest ⬆️ infection risk in RA? steroids, past infection, age, DM? Host factors & Prednisone are Impt. Piling up risk factors is often multiplied! Biggest risk of serious infection and is recurrent serious infection! #EULAR2021 Meet the expert AbbVie session @RheumNow https://t.co/6m0OfsNF1W
      Check out this compilation of our EULAR 2021 Day 1 broadcasts below. You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundclound.com Listen by Clicking below: Day 1a Day 1b
      RT @ARD_BMJ: MUC5B promoter variant is associated with interstitial lung disease.
      Interactions with:
      👉rheumatoid art

      ARD & RMD Open ARD_BMJ

      4 years 3 months ago
      MUC5B promoter variant is associated with interstitial lung disease. Interactions with: 👉rheumatoid arthritis 👉 age 👉 sex Check this Finnish biobank study of 250,000 individuals presented by Antti Palömaki at the Plenary Abstracts Session Wed 02/06 16:15 >LC
      RT @_connectedcare: Patients selected to maximise response & minimise adverse events in RA & PsA trials.

      What i

      Dr Irwin Lim _connectedcare

      4 years 3 months ago
      Patients selected to maximise response & minimise adverse events in RA & PsA trials. What implications does this have when we interpret the data & try to apply in clinic? #EULAR2021 https://t.co/CocKlvjme4
      RT @drdavidliew: Worse dentition is associated with worse RA disease activity.

      And that's the tooth!🙄

      from two big

      David Liew drdavidliew

      4 years 3 months ago
      Worse dentition is associated with worse RA disease activity. And that's the tooth!🙄 from two big German cohorts @CallhoffJ POS0026 #EULAR2021 @RheumNow https://t.co/rjCQ6AtQzq
      RT @uptoTate: ERA & JPsA children & adolescents tx'ed w/ SEC, JUNIPERA 104wk data: longer time to flare vs PBO.

      Dr. Rachel Tate uptoTate

      4 years 3 months ago

      ERA & JPsA children & adolescents tx'ed w/ SEC, JUNIPERA 104wk data: longer time to flare vs PBO. NRI analysis: 87.2%, 83.7%, 67.4%, 38.4% and 24.4% achieved JIA ACR 30/50/70/90/100, respectively. No new safety signals. #EULAR2021 @RheumNow Abstract #LB004 https://t.co/reWawBWfqh https://t.co/9gzKKU1xrm

      ×